Safety and efficacy of cangrelor use in intracranial aneurysms: A Single-arm Meta-analysis and Systematic Review

Background: Dual antiplatelet drugs are important for the treatment of intracranial aneurysms(IAs). However, postoperative complications(mainly Cerebral infarction and Cerebral hemorrhage) continued plaguing doctors and patients. Cangrelor was a newly developed intravenous P2Y12 receptor inhibitor in 2015. Its pharmacological action showed that it may be safer and more effective in the treatment of IAs. Therefore, we conducted a single arm meta-analysis and aystematic review to assess the feasibility of cangrelor in IAs. Data Sources and Methods: We searched PubMed, Cochrane, Web of Science and Embase and Embase for randomized clinical trials and nonrandomized studies of intervention including IAs patients who received cangrelor during operation. Statistical analysis was carried out using R software. Results: We included 6 studies comprising 115 patients. Median age ranged 56-61 from 41 to 86 years. In a pooled analysis, the preventing infarction effective rate of 98% (95% CI 0.93 to 1.00; I 2 =0%) and cerebral hemorrhage rate of 2% (95% CI 0.00 to 0.07; I 2 =25%). Conclusion: In the limited studies published so far, we tentatively believe that cangrelor is safe and effective in IAs. However, we still look forward to more relevant studies to help us further confirm, and the optimal treatment plan can be obtained.